No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 28 of the 30 quarters in the window, leaving 2 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.8x · 10Y median 52.8x · 16th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:47:51.712Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for PRF Technologies Ltd. (PRFX) stock was $0.90 as of Oct 6, 2026, 1:43 PM EDT, up 1.84% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -87.1% · 3-year avg -78.9%/yr · 5-year avg -74.5%/yr
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management.
Drug Manufacturers - Specialty & Generic · Tel Aviv, TA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.12
vs Estimate
$-612.00
Revenue
$7000.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRFX | $72,527 | $0.90 | +1.84% | -87.06% | -74.50% | N/A | N/A |
| 2AKAN | $61,172 | $1.89 | -1.05% | -96.82% | N/A | N/A | vs PRFX |
| 3PBM | $96,046 | $5.05 | -0.59% | -73.54% | N/A | N/A | vs PRFX |
| 4SLXN | $109,400 | $0.26 | -1.84% | -99.31% | N/A | N/A | vs PRFX |
| 5MNDR | $30,755 | $1.25 | -2.39% | -99.03% | N/A | N/A | vs PRFX |
| 6NIVF | $6,241 | $0.10 | -10.18% | -99.99% | N/A | N/A | vs PRFX |
forward FY estimate
N/A
vs Estimate
$7000.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.90
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-516.00 | $-516.00 | $-516.00 | 1 |
| Quarter ending Dec 2026 | $-660.00 | $-660.00 | $-660.00 | 1 |
| Quarter ending Mar 2027 | $-192.00 | $-192.00 | $-192.00 | 1 |
| Quarter ending Jun 2027 | $-204.00 | $-204.00 | $-204.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-176.40 | $-176.40 | $-176.40 | 1 |
| FY 2027 | $-129.60 | $-129.60 | $-129.60 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $6514.00 | $6514.00 | $6514.00 | 1 |
| Quarter ending Dec 2026 | $6062.00 | $6062.00 | $6062.00 | 1 |
| Quarter ending Mar 2027 | $5641.00 | $5641.00 | $5641.00 | 1 |
| Quarter ending Jun 2027 | $5250.00 | $5250.00 | $5250.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $10.31M | $10.31M | $10.31M | 1 |
| FY 2027 | $11.02M | $11.02M | $11.02M | 1 |
